Mechanisms of Anticancer Drug Action

[1]  P. Krammer,et al.  Tumor Immunology , 2018, Medical Immunology.

[2]  A. Hagenbeek,et al.  G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma , 2004, Leukemia.

[3]  J. Tschopp,et al.  The PIDDosome, a Protein Complex Implicated in Activation of Caspase-2 in Response to Genotoxic Stress , 2004, Science.

[4]  E. Slee,et al.  To die or not to die: how does p53 decide? , 2004, Oncogene.

[5]  Boris Zhivotovsky,et al.  DNA damage-induced apoptosis , 2004, Oncogene.

[6]  P. Krammer,et al.  Death receptors in chemotherapy and cancer , 2004, Oncogene.

[7]  C. Rudin,et al.  Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Rebecca A. Ihrie,et al.  Perp-etrating p53-Dependent Apoptosis , 2004, Cell cycle.

[9]  A. Ballestrero,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells , 2004, Clinical Cancer Research.

[10]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[11]  A. Gunasekera,et al.  Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.

[12]  P. Krammer,et al.  Apoptosis in cancer--implications for therapy. , 2004, Seminars in oncology.

[13]  K. Debatin,et al.  Apoptosis pathways in cancer and cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[14]  D. Green,et al.  Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation , 2004, The Journal of cell biology.

[15]  Yigong Shi,et al.  Histone H1.2 as a trigger for apoptosis , 2003, Nature Structural Biology.

[16]  T. Jacks,et al.  Multiple response elements and differential p53 binding control Perp expression during apoptosis. , 2003, Molecular cancer research : MCR.

[17]  Alexei Degterev,et al.  A decade of caspases , 2003, Oncogene.

[18]  K. Lauber,et al.  Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling 1 , 2003, The Journal of Immunology.

[19]  Rebecca A. Ihrie,et al.  Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types , 2003, Current Biology.

[20]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[21]  D. Green,et al.  Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. , 2003, Cancer cell.

[22]  Kyucheol Cho,et al.  Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. , 2003, Cancer research.

[23]  D. Vaux,et al.  Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.

[24]  C. Belka,et al.  Guardians of cell death: the Bcl-2 family proteins. , 2003, Essays in biochemistry.

[25]  Y. Tsujimoto,et al.  Involvement of Histone H1.2 in Apoptosis Induced by DNA Double-Strand Breaks , 2003, Cell.

[26]  D. Green,et al.  p53's Believe It or Not: Lessons on Transcription-Independent Death , 2003, Journal of Clinical Immunology.

[27]  C. Belka,et al.  Disruption of cell death signaling in cancer: impact on disease prognosis and response to therapy. , 2003, Current medicinal chemistry. Anti-cancer agents.

[28]  B. Pützer,et al.  p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. , 2003, Cancer research.

[29]  John Calvin Reed,et al.  Peptides Targeting Caspase Inhibitors* , 2003, The Journal of Biological Chemistry.

[30]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[31]  W. Hahn,et al.  Chemosensitivity linked to p73 function. , 2003, Cancer cell.

[32]  D. Green,et al.  p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation , 2003, Cell Death and Differentiation.

[33]  T. Soussi p53 mutations and resistance to chemotherapy: A stab in the back for p73. , 2003, Cancer cell.

[34]  Johan Hansson,et al.  Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling* , 2003, The Journal of Biological Chemistry.

[35]  Takashi Tsuruo,et al.  Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. , 2003, Cancer research.

[36]  M. Caligiuri,et al.  Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. , 2003, Blood.

[37]  K. Schulze-Osthoff,et al.  Many cuts to ruin: a comprehensive update of caspase substrates , 2003, Cell Death and Differentiation.

[38]  R. Larsson,et al.  Overview of the clinical efficacy of investigational anticancer drugs , 2003, Journal of internal medicine.

[39]  G. Gores,et al.  Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ * , 2002, The Journal of Biological Chemistry.

[40]  P. Scheurich,et al.  TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.

[41]  Ximena Opitz-Araya,et al.  Requirement for Caspase-2 in Stress-Induced Apoptosis Before Mitochondrial Permeabilization , 2002, Science.

[42]  Sten Orrenius,et al.  Caspase-2 Acts Upstream of Mitochondria to Promote Cytochromec Release during Etoposide-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[43]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[44]  Mark D. Johnson,et al.  Peg3/Pw1 Is a Mediator between p53 and Bax in DNA Damage-induced Neuronal Death* , 2002, The Journal of Biological Chemistry.

[45]  G. Salvesen,et al.  IAP proteins: blocking the road to death's door , 2002, Nature reviews. Molecular cell biology.

[46]  Kozo Nakamura,et al.  p53AIP1 regulates the mitochondrial apoptotic pathway. , 2002, Cancer research.

[47]  A. Strasser,et al.  Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins , 2002, Cell Death and Differentiation.

[48]  K. Bhalla,et al.  Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. , 2002, Blood.

[49]  C. Rudin,et al.  A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  Karen L. Siedlecki,et al.  Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  R. Dummer,et al.  Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. , 2002, The Journal of investigative dermatology.

[52]  Judith Roth,et al.  A polymorphic microsatellite that mediates induction of PIG3 by p53 , 2002, Nature Genetics.

[53]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[54]  J. Tschopp,et al.  Defective death receptor signaling as a cause of tumor immune escape. , 2002, Seminars in cancer biology.

[55]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[56]  J. Downward,et al.  The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif* , 2002, The Journal of Biological Chemistry.

[57]  Yuri Lazebnik,et al.  Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease That Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction* , 2002, The Journal of Biological Chemistry.

[58]  D. Green,et al.  CELL DEATH AND IMMUNE PRIVILEGE , 2002, International reviews of immunology.

[59]  M. Gleave,et al.  A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  D. Altieri,et al.  The molecular basis and potential role of survivin in cancer diagnosis and therapy. , 2001, Trends in molecular medicine.

[61]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[62]  D. Green,et al.  The role of Fas ligand in immune privilege , 2001, Nature Reviews Molecular Cell Biology.

[63]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[64]  G. Kroemer,et al.  Organelle-specific initiation of cell death pathways , 2001, Nature Cell Biology.

[65]  G. Krissansen,et al.  Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. , 2001, Journal of the National Cancer Institute.

[66]  A. Ferguson-Smith,et al.  DNA methylation in genomic imprinting, development, and disease , 2001, The Journal of pathology.

[67]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[68]  S. Kyo,et al.  Telomerase activation by histone deacetylase inhibitor in normal cells. , 2001, Nucleic acids research.

[69]  M. Weller,et al.  CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release , 2001, Oncogene.

[70]  Xu Luo,et al.  Endonuclease G is an apoptotic DNase when released from mitochondria , 2001, Nature.

[71]  R. Korneluk,et al.  XIAP, the guardian angel , 2001, Nature Reviews Molecular Cell Biology.

[72]  K. Helin,et al.  Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.

[73]  M. Tohyama,et al.  Activation of Caspase-12, an Endoplastic Reticulum (ER) Resident Caspase, through Tumor Necrosis Factor Receptor-associated Factor 2-dependent Mechanism in Response to the ER Stress* , 2001, The Journal of Biological Chemistry.

[74]  C. Belka,et al.  Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL , 2001, Oncogene.

[75]  R. K Srivastava,et al.  Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways , 2001, Oncogene.

[76]  B. Dörken,et al.  Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[78]  D. Banerjee Genasense (Genta Inc). , 2001, Current opinion in investigational drugs.

[79]  Lakshmi Goyal Cell Death Inhibition Keeping Caspases in Check , 2001, Cell.

[80]  P. Krammer,et al.  CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice , 2001, The Journal of Immunology.

[81]  G. Kroemer,et al.  Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis , 2001, Oncogene.

[82]  K. Khanna,et al.  DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.

[83]  N. Restifo Countering the 'counterattack' hypothesis , 2001, Nature Medicine.

[84]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[85]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[86]  K. Tamai,et al.  Identification of XAF1 as an antagonist of XIAP anti-Caspase activity , 2001, Nature Cell Biology.

[87]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[88]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[89]  K. Kinzler,et al.  Role of BAX in the apoptotic response to anticancer agents. , 2000, Science.

[90]  M. Nau,et al.  Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines , 2000, Breast Cancer Research and Treatment.

[91]  X. Wu,et al.  Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[92]  B. Zhivotovsky,et al.  Distinct Pathways for Stimulation of Cytochrome cRelease by Etoposide* , 2000, The Journal of Biological Chemistry.

[93]  P. Krammer,et al.  A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs , 2000, Molecular and Cellular Biology.

[94]  D. Kufe,et al.  XIAP Regulates DNA Damage-induced Apoptosis Downstream of Caspase-9 Cleavage* , 2000, The Journal of Biological Chemistry.

[95]  A. Wyllie,et al.  Defying death after DNA damage , 2000, Nature.

[96]  F. Sigaux,et al.  Expression and prognostic significance of survivin in de novo acute myeloid leukaemia , 2000, British journal of haematology.

[97]  Claus Belka,et al.  Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis , 2000, Oncogene.

[98]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[99]  I. Bechmann,et al.  Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL) , 2000, The Lancet.

[100]  Yunping Lin,et al.  Pidd, a new death-domain–containing protein, is induced by p53 and promotes apoptosis , 2000, Nature Genetics.

[101]  John Calvin Reed,et al.  BIRinging Chromosomes through Cell Division—And Survivin' the Experience , 2000, Cell.

[102]  B. Dörken,et al.  Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo , 2000, Leukemia.

[103]  I. Herr,et al.  Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-α , 2000, Oncogene.

[104]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[105]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[106]  D. Green Apoptotic Pathways Paper Wraps Stone Blunts Scissors , 2000, Cell.

[107]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[108]  E. Slee,et al.  Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release , 2000, Cell Death and Differentiation.

[109]  N D Marchenko,et al.  Death Signal-induced Localization of p53 Protein to Mitochondria , 2000, The Journal of Biological Chemistry.

[110]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[111]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  N. Restifo Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[113]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[114]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[115]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[117]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[118]  V. Kidd,et al.  Caspase-8 Activation and Bid Cleavage Contribute to MCF7 Cellular Execution in a Caspase-3-dependent Manner during Staurosporine-mediated Apoptosis* , 2000, The Journal of Biological Chemistry.

[119]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[120]  S. Lowe,et al.  PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.

[121]  K. Bhalla,et al.  The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. , 2000, Cancer research.

[122]  D. Green,et al.  p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release* , 2000, The Journal of Biological Chemistry.

[123]  P. Krammer,et al.  Tumor counterattack – concept and reality , 2000, European journal of immunology.

[124]  D. Bowtell,et al.  Pw1/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[125]  A. Chinnaiyan,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[126]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[127]  Junying Yuan,et al.  Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β , 2000, Nature.

[128]  A. Strasser,et al.  Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy , 2000 .

[129]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[130]  E. Slee,et al.  Serial killers: ordering caspase activation events in apoptosis , 1999, Cell Death and Differentiation.

[131]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[132]  M. Weller,et al.  Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells , 1999, Oncogene.

[133]  B. Joseph,et al.  Differences in expression of pro-caspases in small cell and non-small cell lung carcinoma. , 1999, Biochemical and biophysical research communications.

[134]  G. Cohen,et al.  Caspase Activation Involves the Formation of the Aposome, a Large (∼700 kDa) Caspase-activating Complex* , 1999, The Journal of Biological Chemistry.

[135]  A. Strasser,et al.  The great escape: Is immune evasion required for tumor progression? , 1999, Nature Medicine.

[136]  S. Fulda,et al.  Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[137]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[138]  G. Núñez,et al.  Role of cytochrome c and dATP/ATP hydrolysis in Apaf‐1‐mediated caspase‐9 activation and apoptosis , 1999, The EMBO journal.

[139]  W. Dalton,et al.  Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. , 1999, Blood.

[140]  K. Schulze-Osthoff,et al.  The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. , 1999, Immunity.

[141]  B. Dörken,et al.  Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  I. H. Engels,et al.  Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. , 1999, Cancer research.

[143]  I. H. Engels,et al.  Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. , 1999, Blood.

[144]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[145]  E. Solary,et al.  STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. , 1999, Biochemical and biophysical research communications.

[146]  E. Solary,et al.  Fas Ligand-independent, FADD-mediated Activation of the Fas Death Pathway by Anticancer Drugs* , 1999, The Journal of Biological Chemistry.

[147]  F. Shanahan,et al.  Fas counter-attack–the best form of tumor defense? , 1999, Nature Medicine.

[148]  Ruedi Aebersold,et al.  Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.

[149]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[150]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[151]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[152]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[153]  J P Luzio,et al.  Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.

[154]  M. Peter,et al.  Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cells , 1998, Cell Death and Differentiation.

[155]  G. Kroemer,et al.  Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. , 1998, Cancer research.

[156]  T. Mak,et al.  Apaf1 Is Required for Mitochondrial Pathways of Apoptosis and Brain Development , 1998, Cell.

[157]  D. Ferrari,et al.  Differential Regulation and ATP Requirement for Caspase-8 and Caspase-3 Activation during CD95- and Anticancer Drug–induced Apoptosis , 1998, The Journal of experimental medicine.

[158]  N. D’alessandro,et al.  The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis , 1998, Cell Death and Differentiation.

[159]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[160]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[161]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[162]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[163]  L. Bracco,et al.  The requirement for the p53 proline‐rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression , 1998, The EMBO journal.

[164]  José Luis de la Pompa,et al.  Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.

[165]  J. Beckmann,et al.  Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. , 1998, Immunity.

[166]  D. Ferrari,et al.  Apoptosis signaling by death receptors. , 1998, European journal of biochemistry.

[167]  S. Srinivasula,et al.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.

[168]  C. Brady,et al.  The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. , 1998, Journal of immunology.

[169]  V. Cryns,et al.  Proteases to die for. , 1998, Genes & development.

[170]  John Calvin Reed Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  D. Haines,et al.  mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells , 1998, Oncogene.

[172]  M. Manfait,et al.  Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL60 leukemic cells. , 1998, Biochemical and biophysical research communications.

[173]  Alan G. Porter,et al.  Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[174]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[175]  D. Altieri,et al.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma , 1998, The Lancet.

[176]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[177]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[178]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[179]  R. Siegel,et al.  Membrane Oligomerization and Cleavage Activates the Caspase-8 (FLICE/MACHα1) Death Signal* , 1998, The Journal of Biological Chemistry.

[180]  Brent R. Stockwell,et al.  An Induced Proximity Model for Caspase-8 Activation* , 1998, The Journal of Biological Chemistry.

[181]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[182]  Y. Nakamura,et al.  Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. , 1997, Biochemical and biophysical research communications.

[183]  E. Nabel,et al.  Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[184]  M. Martínez-Lorenzo,et al.  Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.

[185]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[186]  H. Blau,et al.  Immune response and myoblasts that express Fas ligand. , 1997, Science.

[187]  M. Peter,et al.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. , 1997, Cancer research.

[188]  I. Herr,et al.  Activation of CD95 (APO‐1/Fas) signaling by ceramide mediates cancer therapy‐induced apoptosis , 1997, The EMBO journal.

[189]  I. Herr,et al.  Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). , 1997, Blood.

[190]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[191]  I. Herr,et al.  The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. , 1997, Cancer research.

[192]  Yusuke Nakamura,et al.  GML sensitizes cancer cells to Taxol by induction of apoptosis , 1997, Oncogene.

[193]  R. Greil,et al.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. , 1997, Cancer research.

[194]  Y. Goltsev,et al.  CASH, a Novel Caspase Homologue with Death Effector Domains* , 1997, The Journal of Biological Chemistry.

[195]  Y. Nakamura,et al.  Cloning of P2XM, a novel human P2X receptor gene regulated by p53. , 1997, Cancer research.

[196]  W. Earnshaw,et al.  Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. , 1997, Blood.

[197]  S. Srinivasula,et al.  FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[198]  J. Houghton,et al.  Thymineless death in colon carcinoma cells is mediated via fas signaling. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[199]  D. Fabbro,et al.  Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. , 1997, Journal of the National Cancer Institute.

[200]  D. Israeli,et al.  A novel p53‐inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis , 1997, The EMBO journal.

[201]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[202]  R. Greil,et al.  Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. , 1997, Blood.

[203]  K. A. McKenna,et al.  p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. , 1997, Cancer research.

[204]  D. Hanahan,et al.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.

[205]  R. Weichselbaum,et al.  Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[206]  K. Isselbacher,et al.  Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[207]  D. Cunningham,et al.  BCL-2 antisense therapy in patients with non-Hodgkin lymphoma , 1997, The Lancet.

[208]  Xiaodong Wang,et al.  DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.

[209]  D. Vaux,et al.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[210]  Mi-Ock Lee,et al.  Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.

[211]  Erwin G. Van Meir,et al.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? , 1997, The Journal of clinical investigation.

[212]  D. Green,et al.  Human lung carcinomas express Fas ligand. , 1997, Cancer research.

[213]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[214]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[215]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[216]  P. Galle,et al.  Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.

[217]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[218]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[219]  Y. Nakamura,et al.  Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. , 1996, Oncogene.

[220]  F. Shanahan,et al.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.

[221]  D. Green,et al.  CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. , 1996, Immunity.

[222]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[223]  A. H. Drummond,et al.  Fas ligand in human serum , 1996, Nature Medicine.

[224]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[225]  D. Green,et al.  Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege , 1995, Science.

[226]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[227]  C. Rudin,et al.  Expression of bcl-xL can confer a multidrug resistance phenotype. , 1995, Blood.

[228]  B. Dörken,et al.  Expression of the bcl‐2 gene family in normal and malignant breast tissue: Low bax‐α expression in tumor cells correlates with resistance towards apoptosis , 1995, International journal of cancer.

[229]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[230]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[231]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[232]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[233]  T. Jacks,et al.  DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.

[234]  P. Johnson,et al.  Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. , 1994, Oncogene.

[235]  K. Kinzler,et al.  p53 tagged sites from human genomic DNA. , 1994, Human molecular genetics.

[236]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[237]  C. Croce,et al.  Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.

[238]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[239]  J. Magaud,et al.  High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 1993, Blood.

[240]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[241]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[242]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[243]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[244]  G. Williams,et al.  The anti-cancer drug etoposide can induce caspase-8 processing and apoptosis in the absence of CD95 receptor-ligand interaction , 2004, Apoptosis.

[245]  D. Altieri Validating survivin as a cancer therapeutic target , 2003, Nature Reviews Cancer.

[246]  D. Altieri Survivin and apoptosis control. , 2003, Advances in cancer research.

[247]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[248]  V. Mikhail,et al.  MINI REVIEW P53: AN UBIQUITOUS TARGET OF ANTICANCER DRUGS , 2002 .

[249]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[250]  S. Srinivasula,et al.  The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity , 2002, Cell Death and Differentiation.

[251]  P. Krammer,et al.  The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. , 2001, Cancer research.

[252]  B. Vanderhyden,et al.  Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. , 2001, Endocrinology.

[253]  K. Schulze-Osthoff,et al.  Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. , 2001, Blood.

[254]  A. Thor,et al.  Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. , 2001, Cancer research.

[255]  Jean-Claude Martinou,et al.  Breaking the mitochondrial barrier , 2001, Nature Reviews Molecular Cell Biology.

[256]  Y. Nakamura,et al.  The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.

[257]  S. Fulda,et al.  Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. , 2000, Blood.

[258]  Aris Persidis,et al.  Cancer multidrug resistance , 1999, Nature Biotechnology.

[259]  A. Strasser,et al.  Does "death receptor" signaling play a role in tumorigenesis and cancer therapy? , 1998, Oncology research.

[260]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[261]  S. Rosenberg,et al.  implications for cancer therapy , 1996 .